Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

New Assays Measure Proteins at Femtogram/mL Sensitivity

Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced the commercial release of its Ultrasensitive Cira™ Assays capable of measuring concentrations of low abundance proteins down to the femtogram/mL level.

"These new ultrasensitive test kits will enable researchers and clinicians to measure analytes at previously undetectable levels without giving up the precision and ease of use of our Cira™ platform. With total assay time of under three hours and the ability to read an entire 96-well plate in under five minutes, these assays are suitable for use in Iarge clinical studies," said Susan Vogt, CEO of Aushon. "In addition, these assays have a quantitative range of up to five logs, enabling researchers to simultaneously measure both the high and low regions of the range for a single analyte."

Added Pete Honkanen, Aushon's founder and COO, "As we've continued to advance the performance of our Cira™ platform, we've been able to achieve detection levels down to single femtograms. Cira™ is the only platform which combines both the productivity of multiplexed assays with ultrasensitive detection levels. This means researchers no longer have to trade off between throughput and sensitivity. These new assays will enable scientists and clinicians to detect and monitor changes in extremely low levels of established disease biomarkers and gain new insights into diagnostics and therapeutic treatments. The first kits available are assays for human cytokines for which the endogenous levels are known to be low, or are important markers for developers of immunotherapies, including IFNg, IL-1b, IL-6, IL-10, and TNFa."


Aushon BioSystems


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Sleep apnea may increase the risk of severe COVID-19, say researchers